{
    "clinical_study": {
        "@rank": "104262", 
        "arm_group": {
            "arm_group_label": "Diagnostic (DCE MRI, DW MRI, MR spectroscopy, FDG PET/CT)", 
            "arm_group_type": "Experimental", 
            "description": "Patients undergo radiation therapy and receive chemotherapy per standard of care. Patients undergo DCE MRI, DW MRI, and MR spectroscopy at baseline, 2-2.5 weeks, 4-5 weeks, and 1 month following radiation therapy completion, and FDG PET/CT at baseline, 2-2.5 weeks, and 4-5 weeks."
        }, 
        "brief_summary": {
            "textblock": "This clinical trial studies magnetic resonance imaging (MRI) and positron emission\n      tomography (PET) imaging in predictive treatment response in patients with stage IB-IVA\n      cervical cancer. Comparing results of diagnostic procedures done before, during and after\n      radiation and chemotherapy may help doctors predict a patient's response to treatment and\n      help plan the best treatment."
        }, 
        "brief_title": "MRI and PET Imaging in Predicting Treatment Response in Patients With Stage IB-IVA Cervical Cancer", 
        "condition": [
            "Cervical Adenocarcinoma", 
            "Cervical Adenosquamous Cell Carcinoma", 
            "Cervical Squamous Cell Carcinoma", 
            "Recurrent Cervical Cancer", 
            "Stage IB Cervical Cancer", 
            "Stage IIA Cervical Cancer", 
            "Stage IIB Cervical Cancer", 
            "Stage IIIA Cervical Cancer", 
            "Stage IIIB Cervical Cancer", 
            "Stage IVA Cervical Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Adenocarcinoma", 
                "Carcinoma", 
                "Carcinoma, Squamous Cell", 
                "Uterine Cervical Neoplasms", 
                "Carcinoma, Adenosquamous"
            ]
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. To assess the value of MRI and PET as a non-invasive predictive assay for therapy outcome\n      in cervical cancer.\n\n      OUTLINE:\n\n      Patients undergo radiation therapy and receive chemotherapy per standard of care. Patients\n      undergo dynamic contrast-enhanced (DCE) MRI, diffusion-weighted (DW) MRI, and magnetic\n      resonance (MR) spectroscopy at baseline, 2-2.5 weeks, 4-5 weeks, and 1 month following\n      radiation therapy completion, and fludeoxyglucose F 18 (FDG) PET/computed tomography (CT) at\n      baseline, 2-2.5 weeks, and 4-5 weeks.\n\n      After completion of study, patients are followed up at least every 4 months for 2 years and\n      then at least every 6 months for 3 years."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients must have histologically confirmed stage IB2-IVA epithelial carcinoma of the\n             cervix, including squamous cell, adeno-, and undifferentiated carcinoma, and\n             excluding small cell/neuroendocrine carcinoma, who will undergo radiation therapy for\n             cervical cancer with curative intent\n\n          -  Surgical staging with retroperitoneal staging and lymphadenectomy is permitted\n\n          -  Patients who will undergo standard radiation therapy with concurrent cisplatin-based\n             chemotherapy for cervical cancer\n\n          -  Patients with no prior radiation therapy to the pelvis\n\n          -  Patients with no contra-indications to magnetic resonance (MR) imaging as stated in\n             the section exclusion criteria\n\n          -  Patients must have adequate renal function: glomerular filtration rate (GFR) >30\n             mL/min/1.73 m^2; for the test-retest sub-study MRI, patients must have a GFR of > 60\n             mL/min/1.73m^2\n\n          -  Ability to understand and the willingness to sign a written informed consent document\n\n        Exclusion Criteria:\n\n          -  Patients with small cell/neuroendocrine cervical carcinoma\n\n          -  Patients who have received any prior pelvic radiation therapy in the area of the\n             tumor that precludes the delivery of a curative dose of pelvic radiation\n\n          -  Medical contraindication to MR imaging (e.g. pacemakers, metallic implants, aneurysm\n             clips, known contrast allergy to gadolinium contrast, pregnancy, nursing mothers,\n             weight greater than 350 pounds, GFR < 30)\n\n          -  Major medical or psychiatric illness that, in the investigator's opinion, would\n             prevent completion of treatment, completion of the study protocol, or interfere with\n             follow-up\n\n          -  Life expectancy of less than 6 months"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "237", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01992861", 
            "org_study_id": "8118", 
            "secondary_id": [
                "NCI-2013-01935", 
                "8118", 
                "P30CA015704", 
                "R01CA155454"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Diagnostic (DCE MRI, DW MRI, MR spectroscopy, FDG PET/CT)", 
                "description": "Undergo DCE MRI", 
                "intervention_name": "dynamic contrast-enhanced magnetic resonance imaging", 
                "intervention_type": "Procedure", 
                "other_name": "DCE-MRI"
            }, 
            {
                "arm_group_label": "Diagnostic (DCE MRI, DW MRI, MR spectroscopy, FDG PET/CT)", 
                "description": "Undergo DW MRI", 
                "intervention_name": "diffusion-weighted magnetic resonance imaging", 
                "intervention_type": "Procedure", 
                "other_name": "diffusion-weighted MRI"
            }, 
            {
                "arm_group_label": "Diagnostic (DCE MRI, DW MRI, MR spectroscopy, FDG PET/CT)", 
                "description": "Undergo MR spectroscopy", 
                "intervention_name": "magnetic resonance spectroscopic imaging", 
                "intervention_type": "Procedure", 
                "other_name": [
                    "1H-nuclear magnetic resonance spectroscopic imaging", 
                    "Proton Magnetic Resonance Spectroscopic Imaging"
                ]
            }, 
            {
                "arm_group_label": "Diagnostic (DCE MRI, DW MRI, MR spectroscopy, FDG PET/CT)", 
                "description": "Undergo FDG PET/CT", 
                "intervention_name": "fludeoxyglucose F 18", 
                "intervention_type": "Radiation", 
                "other_name": [
                    "18FDG", 
                    "FDG"
                ]
            }, 
            {
                "arm_group_label": "Diagnostic (DCE MRI, DW MRI, MR spectroscopy, FDG PET/CT)", 
                "description": "Undergo FDG PET/CT", 
                "intervention_name": "positron emission tomography", 
                "intervention_type": "Procedure", 
                "other_name": [
                    "FDG-PET", 
                    "PET", 
                    "PET scan", 
                    "tomography, emission computed"
                ]
            }, 
            {
                "arm_group_label": "Diagnostic (DCE MRI, DW MRI, MR spectroscopy, FDG PET/CT)", 
                "description": "Undergo FDG PET/CT", 
                "intervention_name": "computed tomography", 
                "intervention_type": "Procedure", 
                "other_name": "tomography, computed"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "March 27, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "Zhibin Huang", 
                    "phone": "252-744-3768"
                }, 
                "facility": {
                    "address": {
                        "city": "Greenville", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27858"
                    }, 
                    "name": "Eastern Carolina University"
                }, 
                "investigator": {
                    "last_name": "Zhibin Huang", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "William T. Yuh", 
                    "phone": "614-293-5166"
                }, 
                "facility": {
                    "address": {
                        "city": "Columbus", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "43210"
                    }, 
                    "name": "Ohio State University"
                }, 
                "investigator": {
                    "last_name": "William T. Yuh", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Nina A. Mayr", 
                    "phone": "206-598-4110"
                }, 
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98109"
                    }, 
                    "name": "Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium"
                }, 
                "investigator": {
                    "last_name": "Nina A. Mayr", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "MRI- and PET-Predictive-Assay of Treatment Outcome in Cancer of the Cervix", 
        "overall_official": {
            "affiliation": "Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium", 
            "last_name": "Nina Mayr", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2021", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Hazard ratios will be calculated. Predictive power of the heterogeneity metrics will be compared and ranked with Federation of Gynecology and Obstetrics (FIGO) stage, lymph node status, histology, hemoglobin level, and tumor anatomic volumes. Multivariate predictive algorithms will be derived by synergizing the predictive power of imaging metrics and clinical prognosticators for clinical translation.", 
                "measure": "Predictive power of the MRI and PET/CT parameters", 
                "safety_issue": "No", 
                "time_frame": "Up to 5 years"
            }, 
            {
                "description": "Clinical/pelvic examination, pap smear, other standard of care investigations as indicated by clinical findings", 
                "measure": "Local control", 
                "safety_issue": "No", 
                "time_frame": "Up to 5 years"
            }, 
            {
                "measure": "Distant metastatic rate", 
                "safety_issue": "No", 
                "time_frame": "Up to 5 years"
            }, 
            {
                "measure": "Disease-free survival", 
                "safety_issue": "No", 
                "time_frame": "Up to 5 years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01992861"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "University of Washington", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "University of Washington", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}